PMID- 24376443
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140624
LR  - 20211021
IS  - 1664-3224 (Print)
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 4
DP  - 2013 Dec 11
TI  - Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells 
      Interface That Augments Anticancer Immunity.
PG  - 438
LID - 10.3389/fimmu.2013.00438 [doi]
LID - 438
AB  - Dendritic cells (DCs) are the sentinel antigen-presenting cells of the immune 
      system; such that their productive interface with the dying cancer cells is 
      crucial for proper communication of the "non-self" status of cancer cells to the 
      adaptive immune system. Efficiency and the ultimate success of such a 
      communication hinges upon the maturation status of the DCs, attained following 
      their interaction with cancer cells. Immature DCs facilitate tolerance toward 
      cancer cells (observed for many apoptotic inducers) while fully mature DCs can 
      strongly promote anticancer immunity if they secrete the correct combinations of 
      cytokines [observed when DCs interact with cancer cells undergoing immunogenic 
      cell death (ICD)]. However, an intermediate population of DC maturation, called 
      semi-mature DCs exists, which can potentiate either tolerogenicity or 
      pro-tumorigenic responses (as happens in the case of certain chemotherapeutics 
      and agents exerting ambivalent immune reactions). Specific combinations of DC 
      phenotypic markers, DC-derived cytokines/chemokines, dying cancer cell-derived 
      danger signals, and other less characterized entities (e.g., exosomes) can define 
      the nature and evolution of the DC maturation state. In the present review, we 
      discuss these different maturation states of DCs, how they might be attained and 
      which anticancer agents or cell death modalities (e.g., tolerogenic cell death 
      vs. ICD) may regulate these states.
FAU - Dudek, Aleksandra M
AU  - Dudek AM
AD  - Laboratory of Cell Death Research and Therapy, Department of Cellular and 
      Molecular Medicine, KU Leuven , Leuven , Belgium.
FAU - Martin, Shaun
AU  - Martin S
AD  - Laboratory of Cell Death Research and Therapy, Department of Cellular and 
      Molecular Medicine, KU Leuven , Leuven , Belgium.
FAU - Garg, Abhishek D
AU  - Garg AD
AD  - Laboratory of Cell Death Research and Therapy, Department of Cellular and 
      Molecular Medicine, KU Leuven , Leuven , Belgium.
FAU - Agostinis, Patrizia
AU  - Agostinis P
AD  - Laboratory of Cell Death Research and Therapy, Department of Cellular and 
      Molecular Medicine, KU Leuven , Leuven , Belgium.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20131211
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
PMC - PMC3858649
OTO - NOTNLM
OT  - antigen
OT  - cancer
OT  - cell death
OT  - chemotherapy
OT  - cytokine
OT  - immunogenic cell death
OT  - immunosurveillance
OT  - phenotypic DC maturation
EDAT- 2014/01/01 06:00
MHDA- 2014/01/01 06:01
PMCR- 2013/01/01
CRDT- 2013/12/31 06:00
PHST- 2013/10/30 00:00 [received]
PHST- 2013/11/23 00:00 [accepted]
PHST- 2013/12/31 06:00 [entrez]
PHST- 2014/01/01 06:00 [pubmed]
PHST- 2014/01/01 06:01 [medline]
PHST- 2013/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2013.00438 [doi]
PST - epublish
SO  - Front Immunol. 2013 Dec 11;4:438. doi: 10.3389/fimmu.2013.00438.